Table 3.

Expression of BTLA, HVEM and CD160 on T cells and tumour cells.

Molecule	Ligand	Expression on haematopoetic cells	Expression on malignancies	Gene mutations and its expressions/SNPs	Ref.
HVEM	BTLA, CD160, LIGHT, lymphotoxin‐α, herpes simplex virus glycoprotein D	T cells, B cells, NK cells, DCs, myeloid cells;	Melanoma, hepatocellular carcinoma, colorectal cancer; MCL, ALL, CLL Melanoma (primary tumour and metastasis), Oesophageal squamous cell carcinoma, Primary plasma cells (Myeloma, plasma cell leukaemia)	Nonsynonymous substitutions in patients with follicular lymphoma ‐ poor prognosis or no difference	Derre et al., 2010, Costello et al., 2003
		T cells: Higher on naïve T cells, drops shortly after activation and than re‐expressed
BTLA	HVEM	T cells, B cells, NK cells, DCs, myeloid cells	CLL, SLL, TA+ CD8 T cells in melanoma, MCL, Marginal zone lympohma, Follicular Lymphoma, Burkitt Lymphoma, Hodgkin's Lymphoma	No data	Watanabe et al., 2003, M'Hidi et al., 2009
		T cells: Increased upon activation (Human and Murine), Higher On Th1 than Th2, Higher expression by CD4 than CD8 T cells
CD160	HVEM, MHC‐I	NK T cells, NKT cells, T cells, γδTcell (transmembrane form only on subpopulation of IL‐15 activated human NK cells)	CLL, MCL, Hairy Cell leukaemia,	No data	Farren et al., 2011, Maiza et al., 1993
		T cells: Highest expression on exhausted and activated CD8 cells, low expression by CD4 T cells